0000950170-24-073772.txt : 20240614
0000950170-24-073772.hdr.sgml : 20240614
20240614170008
ACCESSION NUMBER: 0000950170-24-073772
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240613
FILED AS OF DATE: 20240614
DATE AS OF CHANGE: 20240614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gros David-Alexandre C
CENTRAL INDEX KEY: 0001644489
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36620
FILM NUMBER: 241045727
MAIL ADDRESS:
STREET 1: 220 MARLBOROUGH STREET
STREET 2: #6
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eledon Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001404281
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 19800 MACARTHUR BLVD.
STREET 2: SUITE 250
CITY: IRVINE
STATE: CA
ZIP: 92612
BUSINESS PHONE: 949-238-8090
MAIL ADDRESS:
STREET 1: 19800 MACARTHUR BLVD.
STREET 2: SUITE 250
CITY: IRVINE
STATE: CA
ZIP: 92612
FORMER COMPANY:
FORMER CONFORMED NAME: Novus Therapeutics, Inc.
DATE OF NAME CHANGE: 20170511
FORMER COMPANY:
FORMER CONFORMED NAME: Tokai Pharmaceuticals Inc
DATE OF NAME CHANGE: 20070622
4
1
ownership.xml
4
X0508
4
2024-06-13
0001404281
Eledon Pharmaceuticals, Inc.
ELDN
0001644489
Gros David-Alexandre C
C/O ELEDON PHARMACEUTICALS, INC.
19800 MACARTHUR BLVD STE. 250
IRVINE
CA
92612
true
true
false
false
Chief Executive Officer
false
Stock Option (right to buy)
2.30
2024-06-13
4
A
false
517454
0
A
2033-05-01
Common Stock
517454
517454
D
This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 517,454 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 129,363 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 388,091 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027.
/s/ Paul Little, as attorney-in-fact for David Alexandre C. Gros, M.D.
2024-06-14